These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 20575634)
21. Local cutaneous necrosis secondary to a prolonged peripheral infusion of methylene blue in vasodilatory shock. Dumbarton TC; Gorman SK; Minor S; Loubani O; White F; Green R Ann Pharmacother; 2012 Mar; 46(3):e6. PubMed ID: 22388329 [TBL] [Abstract][Full Text] [Related]
22. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. Wolin MS; Cherry PD; Rodenburg JM; Messina EJ; Kaley G J Pharmacol Exp Ther; 1990 Sep; 254(3):872-6. PubMed ID: 2168487 [TBL] [Abstract][Full Text] [Related]
23. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J; Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554 [TBL] [Abstract][Full Text] [Related]
24. The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review. Saha BK; Burns SL Am J Med Sci; 2020 Oct; 360(4):329-337. PubMed ID: 32631574 [TBL] [Abstract][Full Text] [Related]
25. Impact of methylene blue in addition to norepinephrine on the intestinal microcirculation in experimental septic shock. Nantais J; Dumbarton TC; Farah N; Maxan A; Zhou J; Minor S; Lehmann C Clin Hemorheol Microcirc; 2014; 58(1):97-105. PubMed ID: 25227191 [TBL] [Abstract][Full Text] [Related]
26. Vasopressor-Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review. Puntillo F; Giglio M; Pasqualucci A; Brienza N; Paladini A; Varrassi G Adv Ther; 2020 Sep; 37(9):3692-3706. PubMed ID: 32705530 [TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of the use of vasopressin in sepsis and septic shock. Wilson SJ; Mehta SS; Bellamy MC Expert Opin Drug Saf; 2005 Nov; 4(6):1027-39. PubMed ID: 16255662 [TBL] [Abstract][Full Text] [Related]
35. [Research progress of methylene blue in the treatment of sepsis and septic shock]. Xue J; Lou X; Chen G Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Nov; 33(11):1384-1387. PubMed ID: 34980315 [TBL] [Abstract][Full Text] [Related]
36. Improvement in Hemodynamics After Methylene Blue Administration in Drug-Induced Vasodilatory Shock: A Case Report. Laes JR; Williams DM; Cole JB J Med Toxicol; 2015 Dec; 11(4):460-3. PubMed ID: 26310944 [TBL] [Abstract][Full Text] [Related]
37. Blue dye, green heart. Tan CD; Rodriguez ER Cardiovasc Pathol; 2010; 19(2):125-6. PubMed ID: 18703358 [TBL] [Abstract][Full Text] [Related]
38. Effects of continuous vasopressin infusion in patients with septic shock. Obritsch MD; Jung R; Fish DN; MacLaren R Ann Pharmacother; 2004; 38(7-8):1117-22. PubMed ID: 15178740 [TBL] [Abstract][Full Text] [Related]
39. Role of corticosteroids in septic shock. Burry LD; Wax RS Ann Pharmacother; 2004 Mar; 38(3):464-72. PubMed ID: 14970369 [TBL] [Abstract][Full Text] [Related]
40. The soluble guanylate cyclase inhibitor methylene blue evokes preterm delivery and fetal growth restriction in a mouse model. Tiboni GM; Giampietro F; Lamonaca D In Vivo; 2001; 15(4):333-7. PubMed ID: 11695226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]